Current Studies
Eosinophilic Esophagitis
Eosinophilic Esophagitis is a chronic immune system disease. Typically presents with difficulty swallowing or food becoming lodged in the esophagus. We are currently seeking participants 18 years or older who have been diagnosed with EOE or have a subjective reporting of four or more episodes of dysphagia over a two week period. Participants receive all study related care and medication at no cost. No insurance is required.
Crohn’s Disease
IM011-023 Study
The purpose of the IM011-023 study is to evaluate how well an oral investigational drug (called BMS-986165) works and how safe it is for patients with moderately to severely active Crohn’s disease. If eligible to enroll in this study, you may receive the study drug or placebo (a pill that looks like the study drug but does not contain an active medicine). All study-related medical procedures and tests will be provided at no cost to you.
Ulcerative Colitis
IM011-024 Study
Have you been diagnosed with Ulcerative Colitis (UC)? The Louisiana Research Center is conducting a clinical study for subjects with moderate to severe UC. You may be eligible to enroll. Learn more by clicking the link below. Participants receive all study related care and medication at no cost. Possible compensation for time and travel to each study participant.
Nonalcoholic steatohepatitis (NASH)
MIRNA Study
Fatty liver disease is a common but ‘silent’ disease, which means that most people are completely unaware that they have it. As there are no symptoms to alert you to the problem, the fat in the liver keeps building up, and can result in a condition known as non-alcoholic steatohepatitis (NASH). Consider taking the first step towards finding out if you have NASH and could be eligible to join a clinical research study.
Nonalcoholic steatohepatitis (NASH)
ESSENCE Study
NASH is a chronic and progressive disease caused by fat deposition in the liver, which cause inflammation and damage of the liver. If not treated, NASH can develop into cirrhosis, liver failure and cancer, which are all severe diseases. It is unknown why some people develop NASH and others don’t, but people with certain medical conditions such as type 2 diabetes, obesity and high cholesterol are at a higher risk of developing this disease. Consider participating in the ESSENCE study evaluating an investigational drug for its ability to treat NASH.
Nonalcoholic steatohepatitis (NASH)
ION224-CS2 study
The ION224-CS2 study is a clinical research study testing whether an investigational* study drug can safely improve liver health in people with NASH. There are currently no approved drugs for NASH. The ION224-CS2 study is researching a way to meet this currently unmet need.
Clostridium difficile
PUNCH CD3-OLS Study
Does your C. diff diarrhea keep returning? If yes, you may have recurrent C. diff infection. A research study at the Louisiana Research Center aims to stop C. diff from returning. Study patients will receive expert medical care and specialized attention from the study team. The cost of the study drug, study-related tests, as well as study follow-up calls and visits will be covered by the study sponsor, Rebiotix.
Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome is a common disorder that affects the large intestine. Symptoms including bloating, gas, diarrhea, constipation or both and abdominal pain. We are currently enrolling in an IBS with abdominal Pain. Participants must be 18-70 years of age with a clinical diagnosis of IBS-C or IBS-D.
Clostridium difficile
ART24-01-001 Study
Did you know even when successfully treated, C. diff recurrence is common? Up to 25% of people with C. diff will get infected again. A study at the Louisiana Research Center is recruiting individuals who are currently being treated for C. diff. infection. All study-related visits, tests, and study medications will be provided to participants at no cost by the biopharmaceutical company sponsoring this clinical trial.
Primary Sclerosing Cholangitis
Gilead GS-US-428-4194 Study
In the battle against primary sclerosing cholangitis (PSC), the best team is research and you. If you have been diagnosed with primary sclerosing cholangitis, consider participating in the PRIMIS research study. The study is evaluating the safety and effectiveness of an investigational drug to understand if it can potentially slow the progress of liver damage caused by PSC.